

REMARKS

Interview Summary

The substance of the Interview on February 17, 2004 between Examiner DeBerry, Examiner Eyler, Dr. Carney and the undersigned is set forth in the Interview Summary provided to Applicants by Examiner DeBerry after the Interview. The Interview Summary is incorporated herein by reference.

Claim Amendments and new Claims 45-65

The subject matter of Claim 4, as amended, and new Claims 45-65 is fully supported in the present application as filed July 19, 2001. Support can be found in the specification, for example, at page 3, lines 3-6; page 3, lines 10-15; page 5, line 3, which incorporates by reference the entire contents of U.S. Patent Nos. 5,500,412 and 5,352,664; in the two paragraphs added at page 6, line 16, between paragraph 1 and paragraph 2 (see the Reply to Restriction Requirement and Preliminary Amendment, filed December 6, 2002); at page 6, line 1 to page 8, line 15; page 9, line 8 to page 12, line 16; page 13, lines 23-25; and in originally filed Claims 1-37. No new matter has been added by the new claims or by the amendment to Claim 4.

"Amide"

Applicants wish to clarify that the use of the term "amide" in the subject application is in accordance with the definition recognized and accepted by those skilled in the art. Specifically, the term "amide" is understood in the art to define a functional group generically. A molecule amidated with "-NH₂" at the C-terminus (i.e., wherein the -COOH group at the C-terminus is replaced with -CONH₂) is one example of an amide. Any interpretation of Applicants' prior remarks to the contrary is incorrect and not intended.

Sequence Listing

Transmitted concurrently herewith is a copy of a Substitute "Sequence Listing" in paper form (sheets 1/3 through 3/3) comprising SEQ ID NOs. 1-6 for the above-identified patent application as required by 37 C.F.R. §§ 1.825(a) and 1.821(c), and a copy of the Substitute

"Sequence Listing" in computer readable form as required by 37 C.F.R. §§ 1.825(b) and 1.821(e). Please replace the "Sequence Listing" filed on December 30, 2003 (sheets 1/3 through 3/3) with the Substitute "Sequence Listing" filed concurrently herewith.

The Substitute Sequence Listing filed concurrently herewith correctly recites that SEQ ID NO.: 6 consists of the 23 amino acid sequence Ala-Gly-Try-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val and that the C-terminal valine of SEQ ID NO.: 6 is amidated. Support for this correction to the sequence listing is found in the amended specification, for example, at page 7, lines 19-22, where it is stated that SEQ ID NO.: 6 has the identical amino acid sequence of SEQ ID NO.: 5 and also contains a C-terminal amide.


As required by 37 C.F.R. § 1.825(b), Applicants' Attorney hereby states that the contents of the Substitute "Sequence Listing" in paper form and in the computer readable form submitted concurrently herewith are the same and, as required by 37 C.F.R. § 1.825(a), also states that the submission includes no new matter.

CONCLUSION

In view of the above amendments and remarks, it is believed that all claims are in condition for allowance, and it is respectfully requested that the application be passed to issue. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 
Steven G. Davis
Registration No. 39,652
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: February 20 2004